P
POSEIDA THERAPEUTICS INC
NASDAQ: PSTX (Poseida Therapeutics, Inc.)
Last update: 3 hours ago3.95
0.34 (9.42%)
| Previous Close | 3.61 |
| Open | 3.67 |
| Volume | 723,572 |
| Avg. Volume (3M) | 504,718 |
| Market Cap | 382,982,528 |
| Price / Sales | 6.08 |
| Price / Book | 10.62 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2024 - 12 Aug 2024 |
| Profit Margin | -40.28% |
| Operating Margin (TTM) | 27.52% |
| Diluted EPS (TTM) | -0.630 |
| Quarterly Revenue Growth (YOY) | 667.20% |
| Total Debt/Equity (MRQ) | 94.86% |
| Current Ratio (MRQ) | 3.20 |
| Operating Cash Flow (TTM) | -15.02 M |
| Levered Free Cash Flow (TTM) | -22.24 M |
| Return on Assets (TTM) | -13.11% |
| Return on Equity (TTM) | -57.63% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Poseida Therapeutics, Inc. | Mixed | Mixed |
AIStockmoo Score
-1.2
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -1.5 |
| Technical Oscillators | 0.0 |
| Average | -1.17 |
|
Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumours. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 27.64% |
| % Held by Institutions | 58.44% |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |